You are viewing the site in preview mode

Skip to main content

Table 6 Variables associated with the early clinical response of teicoplanin therapy in patients with complicated MRSA infections: univariate and multivariate analyses

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Factors No of patients with early clinical response (%) Univariate analysis Multivariate analysis
Patients with factor Patients without factor Crude odds ratio (95% CI) P-value Adjusted odds ratio (95%CI) P-value
Enhanced high dose loading regimen 16/23 (69.6%) 38/53 (71.7%) 0.90 (0.31–2.63) 0.851   
Teicoplanin initial Cmin ≥20 μg/mL 31/39 (79.5%) 23/37 (62.2%) 2.36 (0.09–3.95) 0.096 3.95 (1.25–12.53) 0.020
Blood stream infection 19/22 (86.4%) 33/54 (64.8%) 3.44 (0.90–13.13) 0.060 4.55 (1.10–18.77) 0.036
Respiratory infection 33/50 (66.0%) 21/26 (80.8%) 0.46 (0.15–1.44) 0.178   
Osteomyelitis and arthritis 6/9 (66.7%) 48/67 (71.6%) 0.79 (0.18–3.49) 0.713   
Central nervous system 0/1 (0.0%) 54/75 (72.0%) – 0.289   
Mixed infection with Gram-negative organisms 22/34 (64.7%) 32/42 (76.2%) 0.57 (0.21–1.58) 0.272   
Therapy for definitive fungal infections 2/2 (100.0%) 52/74 (70.3%) – 1.000   
Sex (male) 37/52 (71.2%) 17/24 (70.8%) 1.02 (0.35–2.95) 0.977   
Age (> 65 years) 38/57 (66.7%) 16/19 (84.2%) 0.38 (0.10–1.45) 0.144   
eGFR< 30 mL/min/1.73 m2 8/13 (61.5%) 46/63 (73.0%) 0.59 (0.17–2.06) 0.504   
Body mass index < 18.5 22/25 (88.0%) 32/51 (62.7%) 4.35 (1.15–16.52) 0.023 2.94 (0.69–12.41) 0.143
Body mass index ≥25 4/6 (66.7%) 50/70 (71.4%) 0.80 (0.14–4.72) 1.000   
Heart disease 29/37 (78.4%) 25/39 (64.1%) 2.03 (0.73–5.63) 0.170   
Chronic renal failure 11/17 (64.7%) 43/59 (72.9%) 0.68 (0.22–2.15) 0.552   
Diabetes mellitus 13/20 (65.0%) 41/56 (73.2%) 0.68 (0.23–2.03) 0.487   
Collagen disease 5/10 (50.0%) 49/66 (74.2%) 0.35 (0.09–1.35) 0.142   
Chronic respiratory disease 4/8 (50.0%) 50/68 (73.5%) 0.36 (0.08–1.59) 0.219   
Inflammatory bowel disease 7/9 (77.8%) 47/67 (70.1%) 1.49 (0.28–7.80) 1.000   
Intensive care unit stay (> 3 days) 13/22 (59.1%) 41/54 (75.9%) 0.46 (0.16–1.31) 0.142   
Liver cirrhosis/chronic hepatic dysfunction 6/12 (50.0%) 48/64 (75.0%) 0.33 (0.09–0.28) 0.094 0.28 (0.07–1.19) 0.084
Malignant tumor 23/33 (69.7%) 31/43 (72.1%) 0.89 (0.33–2.41) 0.819   
Total parenteral nutrition 10/16 (62.5%) 44/60 (73.3%) 0.61 (0.19–1.94) 0.536   
Serum albumin < 2.5 g/dL (median) 32/43 (74.4%) 22/33 (66.7%) 1.46 (0.54–3.94) 0.460   
Ventilator use 11/22 (50.0%) 43/54 (79.6%) 0.26 (0.09–0.74) 0.010 0.54 (0.16–1.86) 0.330
Surgery within 28 days 10/14 (71.4%) 44/62 (71.0%) 1.02 (0.28–3.69) 1.000   
Transplantation 2/3 (66.7%) 52/73 (71.2%) 0.81 (0.07–9.39) 1.000   
Steroid use 9/16 (56.3%) 45/60 (75.0%) 0.43 (0.14–1.35) 0.213   
Immunosuppressive therapy 2/3 (66.7%) 52/73 (71.2%) 0.81 (0.07–9.39) 1.000   
Anticancer therapy 8/12 (66.7%) 46/64 (71.9%) 0.78 (0.21–2.92) 0.736   
APACHE II score ≥ 15 17/28 (60.7%) 37/48 (77.1%) 0.46 (0.17 1.27) 0.129   
Teicoplanin-resistant MRSA (MIC ≥4 μg/mL) 0 54/76 (71.1%) – –   
  1. Cmin trough concentration, eGFR estimated glomerular filtration rate, APACHE II Acute physiology and chronic health evaluation II score, MIC minimum inhibitory concentration
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us